Literature DB >> 17264845

The ADRB3 Trp64Arg variant and obesity in African-American breast cancer cases.

R McKean-Cowdin1, X Li, L Bernstein, A McTiernan, R Ballard-Barbash, W J Gauderman, F Gilliland.   

Abstract

OBJECTIVE: To determine if a missense change at codon 64 of ADRB3 (Trp64Arg), a candidate obesity gene, is associated with obesity and levels of subcutaneous or visceral fat in African-American breast cancer cases. Several observational studies have found that women, who are overweight or obese at the time of diagnosis, as well as those who gain weight after diagnosis, are at greater risk for breast cancer recurrence and death than non-overweight women.
DESIGN: Prospective cohort of breast cancer cases.
SUBJECTS: 219 African-American breast cancer patients participating in the Los Angeles component of the Health, Eating, Activity and Lifestyle Study. MEASURES: ADRB3 Trp64Arg genotype, measures of weight including body mass index (BMI), weight gain (weight 5 years before diagnosis compared with weight at 30 months after diagnosis), obesity (BMI> or =30 kg/m(2)), waist/hip circumference and visceral or subcutaneous fat were determined by magnetic resonance imaging.
RESULTS: African-American women who were homozygous for the ADRB3 wild-type allele had significantly higher mean visceral fat levels than women who carried the variant (P=0.04), and were significantly more likely to be obese (odd ratios (OR)=2.1, 95% confidence interval (CI)=1.1-4.2). The association with obesity was most pronounced among women who were premenopausal (OR=4.8, 95% CI=1.3-18), who received chemotherapy for their breast cancer (OR=6.1, 95% CI=1.8-20), or who were not physically active (OR=3.9, 95% CI=1.5-9.7).
CONCLUSION: The wild-type allele of the ADRB3 missense change was associated with measures of obesity in our sample of African-American women. The association was modified by menopausal status, history of chemotherapy and modest levels of physical activity. These results will need to be confirmed in an independent sample.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17264845      PMCID: PMC3063149          DOI: 10.1038/sj.ijo.0803554

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  52 in total

1.  Beta 3-adrenergic-receptor polymorphism: a genetic marker for visceral fat obesity and the insulin resistance syndrome.

Authors:  N Sakane; T Yoshida; T Umekawa; M Kondo; Y Sakai; T Takahashi
Journal:  Diabetologia       Date:  1997-02       Impact factor: 10.122

2.  The relation between visceral fat measurement and torso level--is one level better than another? The Atherosclerosis Risk in Communities Study, 1990-1992.

Authors:  Meghan Warren; Pamela J Schreiner; James G Terry
Journal:  Am J Epidemiol       Date:  2006-01-12       Impact factor: 4.897

3.  Molecular characterization of the human beta 3-adrenergic receptor.

Authors:  L J Emorine; S Marullo; M M Briend-Sutren; G Patey; K Tate; C Delavier-Klutchko; A D Strosberg
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

4.  The beta 3-adrenergic receptor gene and obesity in a population sample of African Americans.

Authors:  W L Lowe; C N Rotimi; A Luke; X Guo; X Zhu; A G Comuzzie; T S Schuh; S Halbach; T J Kotlar; R S Cooper
Journal:  Int J Obes Relat Metab Disord       Date:  2001-01

5.  The Trp64Arg mutation of the beta3-adrenergic receptor is associated with hyperglycemia and current body mass index in Jamaican women.

Authors:  N McFarlane-Anderson; F Bennett; R Wilks; S Howell; C Newsome; K Cruickshank; T Forrester
Journal:  Metabolism       Date:  1998-05       Impact factor: 8.694

Review 6.  Adrenoceptor genes in human obesity.

Authors:  P Arner; J Hoffstedt
Journal:  J Intern Med       Date:  1999-06       Impact factor: 8.989

7.  The biochemical effect of the naturally occurring Trp64-->Arg mutation on human beta3-adrenoceptor activity.

Authors:  F Piétri-Rouxel; B St John Manning; J Gros; A D Strosberg
Journal:  Eur J Biochem       Date:  1997-08-01

8.  A prospective study of body size in different periods of life and risk of premenopausal breast cancer.

Authors:  Elisabete Weiderpass; Tonje Braaten; Cecilia Magnusson; Merethe Kumle; Harri Vainio; Eiliv Lund; Hans-Olov Adami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-07       Impact factor: 4.254

9.  Prevalence and trends in overweight among US children and adolescents, 1999-2000.

Authors:  Cynthia L Ogden; Katherine M Flegal; Margaret D Carroll; Clifford L Johnson
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

10.  Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene.

Authors:  J Walston; K Silver; C Bogardus; W C Knowler; F S Celi; S Austin; B Manning; A D Strosberg; M P Stern; N Raben
Journal:  N Engl J Med       Date:  1995-08-10       Impact factor: 91.245

View more
  2 in total

1.  Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.

Authors:  Alexa Montoya; Clarissa N Amaya; Andres Belmont; Nabih Diab; Richard Trevino; Geri Villanueva; Steven Rains; Luis A Sanchez; Nabeel Badri; Salman Otoukesh; Ali Khammanivong; Danielle Liss; Sarah T Baca; Renato J Aguilera; Erin B Dickerson; Alireza Torabi; Alok K Dwivedi; Aamer Abbas; Karinn Chambers; Brad A Bryan; Zeina Nahleh
Journal:  Oncotarget       Date:  2017-01-24

2.  Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.

Authors:  Heather Spencer Feigelson; Lauren R Teras; W Ryan Diver; Weining Tang; Alpa V Patel; Victoria L Stevens; Eugenia E Calle; Michael J Thun; Mark Bouzyk
Journal:  Breast Cancer Res       Date:  2008-07-08       Impact factor: 6.466

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.